日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/09/01 | 1,881 | 1,886 | 1,848 | 1,886 | -6 | -0.3% | 4,700 |
| 2023/08/31 | 1,932 | 1,932 | 1,892 | 1,892 | -40 | -2.1% | 2,600 |
| 2023/08/30 | 1,958 | 1,965 | 1,932 | 1,932 | -25 | -1.3% | 2,700 |
| 2023/08/29 | 1,928 | 2,010 | 1,926 | 1,957 | +35 | +1.8% | 14,100 |
| 2023/08/28 | 1,882 | 1,944 | 1,853 | 1,922 | +47 | +2.5% | 8,200 |
| 2023/08/25 | 1,832 | 1,884 | 1,832 | 1,875 | +20 | +1.1% | 4,200 |
| 2023/08/24 | 1,833 | 1,855 | 1,833 | 1,855 | +28 | +1.5% | 1,500 |
| 2023/08/23 | 1,835 | 1,835 | 1,827 | 1,827 | -8 | -0.4% | 800 |
| 2023/08/22 | 1,827 | 1,835 | 1,827 | 1,835 | +8 | +0.4% | 700 |
| 2023/08/21 | 1,828 | 1,828 | 1,826 | 1,827 | -1 | -0.1% | 400 |
| 2023/08/18 | 1,823 | 1,838 | 1,821 | 1,828 | -14 | -0.8% | 1,700 |
| 2023/08/17 | 1,827 | 1,850 | 1,815 | 1,842 | +9 | +0.5% | 5,900 |
| 2023/08/16 | 1,835 | 1,860 | 1,822 | 1,833 | -2 | -0.1% | 3,800 |
| 2023/08/15 | 1,831 | 1,835 | 1,820 | 1,835 | +10 | +0.5% | 2,200 |
| 2023/08/14 | 1,828 | 1,833 | 1,825 | 1,825 | -3 | -0.2% | 4,500 |
| 2023/08/10 | 1,819 | 1,828 | 1,815 | 1,828 | +5 | +0.3% | 2,500 |
| 2023/08/09 | 1,829 | 1,833 | 1,823 | 1,823 | -2 | -0.1% | 1,600 |
| 2023/08/08 | 1,826 | 1,835 | 1,824 | 1,825 | -3 | -0.2% | 1,500 |
| 2023/08/07 | 1,830 | 1,830 | 1,828 | 1,828 | -2 | -0.1% | 500 |
| 2023/08/04 | 1,836 | 1,837 | 1,830 | 1,830 | -10 | -0.5% | 5,000 |
| 2023/08/03 | 1,855 | 1,859 | 1,840 | 1,840 | -15 | -0.8% | 5,800 |
| 2023/08/02 | 1,896 | 1,896 | 1,851 | 1,855 | -41 | -2.2% | 2,400 |
| 2023/08/01 | 1,870 | 1,925 | 1,859 | 1,896 | +38 | +2% | 7,400 |
| 2023/07/31 | 1,868 | 1,869 | 1,851 | 1,858 | +8 | +0.4% | 4,100 |
| 2023/07/28 | 1,908 | 1,925 | 1,850 | 1,850 | -77 | -4% | 18,400 |
| 2023/07/27 | 1,929 | 1,933 | 1,911 | 1,927 | ±0 | ±0% | 4,300 |
| 2023/07/26 | 1,905 | 1,928 | 1,905 | 1,927 | +15 | +0.8% | 3,800 |
| 2023/07/25 | 1,912 | 1,919 | 1,897 | 1,912 | ±0 | ±0% | 2,800 |
| 2023/07/24 | 1,894 | 1,913 | 1,876 | 1,912 | +42 | +2.2% | 5,900 |
| 2023/07/21 | 1,869 | 1,897 | 1,869 | 1,870 | -10 | -0.5% | 3,100 |
| 2023/07/20 | 1,863 | 1,901 | 1,863 | 1,880 | +15 | +0.8% | 2,900 |
| 2023/07/19 | 1,863 | 1,865 | 1,839 | 1,865 | +32 | +1.7% | 2,400 |
| 2023/07/18 | 1,869 | 1,869 | 1,833 | 1,833 | -38 | -2% | 4,600 |
| 2023/07/14 | 1,901 | 1,901 | 1,871 | 1,871 | -36 | -1.9% | 5,500 |
| 2023/07/13 | 1,902 | 1,911 | 1,895 | 1,907 | +5 | +0.3% | 5,200 |
| 2023/07/12 | 1,901 | 1,912 | 1,901 | 1,902 | -1 | -0.1% | 3,800 |
| 2023/07/11 | 1,929 | 1,929 | 1,901 | 1,903 | -26 | -1.3% | 5,000 |
| 2023/07/10 | 1,915 | 1,936 | 1,910 | 1,929 | +35 | +1.8% | 5,000 |
| 2023/07/07 | 1,902 | 1,904 | 1,890 | 1,894 | -8 | -0.4% | 3,700 |
| 2023/07/06 | 1,917 | 1,917 | 1,902 | 1,902 | -14 | -0.7% | 1,900 |
| 2023/07/05 | 1,919 | 1,938 | 1,910 | 1,916 | -10 | -0.5% | 3,500 |
| 2023/07/04 | 1,931 | 1,940 | 1,911 | 1,926 | -6 | -0.3% | 3,500 |
| 2023/07/03 | 1,913 | 1,933 | 1,913 | 1,932 | +12 | +0.6% | 1,200 |
| 2023/06/30 | 1,925 | 1,925 | 1,907 | 1,920 | +25 | +1.3% | 3,500 |
| 2023/06/29 | 1,930 | 1,930 | 1,895 | 1,895 | -38 | -2% | 7,100 |
| 2023/06/28 | 1,920 | 1,939 | 1,920 | 1,933 | +26 | +1.4% | 3,900 |
| 2023/06/27 | 1,899 | 1,913 | 1,880 | 1,907 | +8 | +0.4% | 7,700 |
| 2023/06/26 | 1,866 | 2,112 | 1,849 | 1,899 | +42 | +2.3% | 45,400 |
| 2023/06/23 | 1,854 | 1,863 | 1,853 | 1,857 | +11 | +0.6% | 2,900 |
| 2023/06/22 | 1,856 | 1,856 | 1,846 | 1,846 | +14 | +0.8% | 3,200 |
301～
350
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
| ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ＶＩＳ | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム
